Cancer Prevention Pharmaceuticals is a clinical stage company developing therapeutics to reduce the risk and recurrence of cancer and rare diseases.
CPP’s innovative technology addresses polyamine metabolism, immune regulation and inflammation to reduce cancer risk and impact other diseases.
These two processes have long been implicated in cancer development but never successfully utilized together to exploit and treat cancer precursors until now.
Recent News from CPP
CPP has submitted a Marketing Authorization Application (MAA) to the EMA for CPP-1X/sul for treatment of adults with FAP. Read the announcement.
CPP has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval for CPP-1X/sul for treatment of adults with FAP. Read the full announcement.
CPP sponsored the FAP-310 Pivotal Phase 3 Trial of our lead product, CPP-1X/sul, for Familial Adenomatous Polyposis (FAP). CPP-1X/sul has been granted “Fast Track” and “Orphan Drug” designation from FDA. An NDA and MAA has been filed.
With the National Cancer Institute (NCI) and SWOG, CPP is also co-sponsoring the PACES Phase 3 Trial in colon cancer survivors which is currently recruiting participants.
CPP’s product pipeline includes pharmaco-prevention therapies to address GI cancers, pediatric cancers and early-onset Type 1 diabetes.
CPP’s pharmaco-prevention approach has been used with success in other disease categories such as cardiovascular, neuromuscular, and infectious disease but has yet to be applied to cancer.
